医学
心力衰竭
射血分数
重症监护医学
缬沙坦
临床试验
医疗保健
食品药品监督管理局
心脏病学
内科学
药理学
血压
经济增长
经济
作者
Rahul Gupta,Muling Lin,Theresa Maitz,David Egeler,Aayaan Sood,Wilbert S. Aronow,Yasotha Rajeswaran,Amy M. Ahnert,Apurva Vyas,William H. Frishman,Gregg M. Lanier
出处
期刊:Cardiology in Review
[Ovid Technologies (Wolters Kluwer)]
日期:2022-01-21
卷期号:31 (2): 87-92
被引量:3
标识
DOI:10.1097/crd.0000000000000431
摘要
Heart failure (HF) affects 6.2 million Americans and is increasing annually in its frequency. Treatment of HF has been at the forefront of medical advancements due to the financial burden on our health care system. As such, changes to the guidelines regarding standard of care have been evolving over the last decade with the recent additions of sacubitril-valsartan and sodium glucose co-transporter-2 inhibitors to standard of care in the treatment of HF. Despite the aforementioned expansions in treatment options, HF continues to have a significant impact on the American health care system. Most recently, a novel drug vericiguat that targets an unprecedented pathway for the treatment of HF was Food and Drug Administration approved for the management of patients with HF with a reduced ejection fraction with a recent hospitalization or need for outpatient intravenous diuretics. In clinical trials, vericiguat was associated with a reduction in death from cardiovascular causes and first hospitalization in comparison to placebo. The aim of this review is to provide a comprehensive literature analysis of the various trials surrounding the approval of vericiguat and to both inform and synthesize the data surrounding the clinical use of vericiguat. The introduction of Vericiguat should be considered as a treatment option in patients to decrease the mortality/morbidity of HF with reduced ejection fraction and to increase the quality of life.
科研通智能强力驱动
Strongly Powered by AbleSci AI